# Oxford Endovascular

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxford-endovascular

- Industry: Medical Devices & Equipment
- Headquarters: Oxford, UK
- Website: www.oxfordendovascular.com
- Total disclosed funding: $21M
- Latest round: Series A (Jan 24, 2024)
- Investors on record: 8

## About

Founded in 2015 and based in Oxford, UK, Oxford Endovascular Limited is a spin-out from Oxford University that operates as a medical technology company. In January 2024, Oxford Endovascular Limited raised GBP 8.07 million in Series A funding led by Parkwalk Advisors, Norcliffe Capital, Oxford Sciences Enterprises, and Vulpes Investment Management. The Series A round of financing values Oxford Endovascular Limited at GBP 40.63 million post-money. As of 2024, the company is led by its CEO, Mike Karim.

Oxford Endovascular offers medical devices for neurovascular diseases. The company developed a device called OXIFLOW to treat brain aneurysms.

The company plans to use the funds raised in January 2024 to support product development.

## Funding rounds

- Series A, Jan 24, 2024, $10M — Parkwalk Advisors, Vulpes Investment Management, Oxford Sciences Enterprises, Norcliffe Capital, University of Oxford
- Series A, Feb 19, 2021, $11M — Parkwalk Advisors, University of Oxford, Vulpes Investment Management, Oxford Sciences Enterprises, Perivoli Innovations, Oxford Investment Consultants, Additio Investment Group

## Investors

- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series A
- University of Oxford — Series A
- Vulpes Investment Management (https://capitalatlas.ai/funds/vulpes-investment-management) — Series A
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series A
- Perivoli Innovations (https://capitalatlas.ai/funds/perivoli-innovations) — Series A
- Oxford Investment Consultants — Series A
- Additio Investment Group (https://capitalatlas.ai/funds/additio-investment-group) — Series A
- Norcliffe Capital (https://capitalatlas.ai/funds/norcliffe-capital) — Series A